Keylynk-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

A Rimner, WVV Lai, R Califano, SK Jabbour, C Faivre-Finn, BC Cho, T Kato, JM Yu, L Yu, B Zhao, MC Pietanza, LA Byers

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Number of pages3
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this